SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a - 16 OR 15d - 16 OF
THE SECURITIES EXCHANGE ACT OF 1934

For the month of May, 2007

SkyePharma PLC

(Translation of registrant's name into English)

SkyePharma PLC, 105 Piccadilly, London W1J 7NJ England

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40F.

Form 20-F X Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No X

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- _______

   TWICE DAILY ZYFLO CR™ (ZILEUTON) EXTENDED-RELEASE TABLETS APPROVED BY
                          THE FDA FOR ASTHMA



LONDON, UK, Thursday, May 31, 2007 - SkyePharma PLC (LSE: SKP) today announces
that the U.S. Food and Drug Administration (FDA) has approved Critical
Therapeutics, Inc.'s (Nasdaq: CRTX) New Drug Application (NDA) for twice-daily
ZYFLO CR™ (zileuton) extended-release tablets.  ZYFLO CR uses SkyePharma PLC's
proprietary Geomatrix® drug delivery technology, which controls the amount and
rate of drug released into the body.

ZYFLO CR and ZYFLO® (zileuton tablets) are the only FDA-approved leukotriene
synthesis inhibitors for the prophylaxis and chronic treatment of asthma in
adults and children 12 years of age and older.  ZYFLO CR and ZYFLO are not
indicated for use in the reversal of bronchospasm in acute asthma attacks, but
can be continued during acute exacerbations of asthma.  Leukotrienes are
inflammatory mediators in asthma that can trigger asthma symptoms, including
inflammation, swelling, bronchoconstriction and mucus secretion.  Critical
Therapeutics expects to begin marketing ZYFLO CR in the U.S. together with its
co-promotion partner, Dey, L.P. (DEY) in the autumn of 2007.

Frank Condella, Chief Executive Officer of SkyePharma, said: "The approval of
ZYFLO CR is another successful application of our Geomatrix oral
controlled-release technology.  We continue our focus on oral and inhalation
products as we build our business moving forward."

Upon the launch of ZYFLO CR, Critical Therapeutics and DEY's combined sales
force of 240 representatives will begin promoting ZYFLO CR to approximately
15,000 allergists, pulmonologists and primary care physicians across the U.S.
SkyePharma will receive a high mid single digit royalty on sales of ZYFLO CR.

For further information please contact:

SkyePharma PLC                        Frank Condella           +44 20 7491 1777
                                      Ken Cunningham
                                      Peter Grant

Financial Dynamics (UK Enquiries)     David Yates              +44 20 7831 3113
                                      Deborah Scott

Trout Group (US Enquiries)            Christine Labaree        +1 617 583 1308
                                      Seth Lewis


About SkyePharma PLC
Using its proprietary drug delivery technologies, SkyePharma develops new
formulations of known molecules to provide a clinical advantage and life-cycle
extension. The Company has eleven approved products in the areas of oral,
inhalation and topical delivery that are marketed throughout the world by
leading pharmaceutical companies.

For more information, visit www.skyepharma.com


About ZYFLO CR and ZYFLO

ZYFLO CR and ZYFLO are the only FDA-approved leukotriene synthesis inhibitors
for the prophylaxis and chronic treatment of asthma in adults and children 12
years of age and older.  ZYFLO CR and ZYFLO are not indicated for use in the
reversal of bronchospasm in acute asthma attacks.  Therapy with ZYFLO CR and
ZYFLO CR can be continued during acute exacerbations of asthma.

The recommended dose of ZYFLO CR is two 600 mg extended-release tablets twice
daily, within one hour after morning and evening meals, for a total daily dose
of 2400 mg.  The recommended dose of ZYFLO is one 600 mg immediate-release
tablet four times a day for a total daily dose of 2400 mg.

ZYFLO CR and ZYFLO are contraindicated in patients with active liver disease or
transaminase elevations greater than or equal to three times the upper limit of
normal.  A small percentage of patients treated with ZYFLO CR (2.5%) and ZYFLO
(1.9%) in placebo-controlled trials showed an increased release of a liver
enzyme known as ALT and bilirubin (an orange or yellowish pigment in bile).  As
a result, the level of liver enzymes in patients treated with ZYFLO CR and ZYFLO
should be measured by a simple blood test.  It is recommended that physicians
perform this test before administering ZYFLO CR and ZYFLO and repeat the test on
a regular basis while patients are on the medication.  Patients taking ZYFLO CR
and theophylline should reduce the theophylline dose by 50%.  Patients taking
ZYFLO CR and propranolol or warfarin should be monitored and doses adjusted as
appropriate.  Most common side effects associated with the use of ZYFLO CR and
ZYFLO are sinusitis, nausea and pharyngolaryngeal pain and abdominal pain, upset
stomach and nausea, respectively.


For full prescribing information for ZYFLO CR, please visit www.zyflocr.com or
call Critical Therapeutics at +1-866-835-8216 to request medical information.

For full prescribing information for ZYFLO, please visit www.zyflo.com or call
+1-866-835-8216 to request medical information.

ZYFLO® and ZYFLO CR™ are trademarks of Critical Therapeutics, Inc.
Geomatrix® is a registered trademark of SkyePharma PLC.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

                                                                  SkyePharma PLC

                                                                      By: /s/ John Murphy

                                                                       Name: John Murphy
                                                                          Title: Company Secretary

Date: May 31, 2007

SKYEPHARMA PLC 6-K